TY - JOUR
T1 - The successful treatment of refractory polyarteritis nodosa using infliximab
AU - Matsuo, Satoko
AU - Hayashi, Keigo
AU - Morimoto, Eisaku
AU - Kato, Ayako
AU - Sada, Kenei
AU - Watanabe, Haruki
AU - Takano-Narazaki, Mariko
AU - Sunahori-Watanabe, Katsue
AU - Kawabata, Tomoko
AU - Wada, Jun
N1 - Funding Information:
This work was supported by grants from the Research Committee of Intractable Vasculitis Syndrome of the Ministry of Health, Labour, and Welfare of Japan, and the Study Group for Strategic Exploration of Drug Seeds for ANCA-associated Vasculitis and Construction of Clinical Evidence from the Japan Agency for Medical Research and Development (AMED).
Publisher Copyright:
© 2017 The Japanese Society of Internal Medicine.
PY - 2017
Y1 - 2017
N2 - Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.
AB - Polyarteritis nodosa (PAN), characterized by arteritis of medium-sized blood vessels, is usually treated with a combination of glucocorticoids and immunosuppressants; however, some cases are refractory to these treatments. We herein report the case of a man with PAN that was refractory to various immunosuppressive treatments, including cyclophosphamide, methotrexate, and rituximab. After infliximab (IFX) treatment was initiated, his symptoms improved dramatically and remission was maintained. IFX is considered to be an effective alternative treatment for PAN which proves to be refractory to several immunosuppressive treatments.
KW - Infliximab
KW - Polyarteritis nodosa
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=85020074121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020074121&partnerID=8YFLogxK
U2 - 10.2169/internalmedicine.56.8235
DO - 10.2169/internalmedicine.56.8235
M3 - Article
C2 - 28566612
AN - SCOPUS:85020074121
SN - 0918-2918
VL - 56
SP - 1435
EP - 1438
JO - Internal Medicine
JF - Internal Medicine
IS - 11
ER -